As scientists, we are challenged to discover treatments for cancer patients. Yet, the lack of available models relevant to tumor type, disease progression, and population diversity impedes our progress towards rapid advancements in translational medicine.
We are committed to providing authenticated cancer models that lead to breakthroughs in translational research. To this end, ATCC produces the materials and standards for drug screening, tumor mechanisms, cancer immunology, and cancer diagnostics that scientists need to accomplish innovative research. New models such as organoids, conditionally reprogrammed cells, luciferase expressing reporter cell lines, isogenic CRISPR/Cas9 genome-edited cell lines, and epithelial-mesenchymal transition reporter cell lines are essential for your cutting-edge cancer research.
In the fight against cancer, we can provide you with access to a wide variety of model systems to elucidate the mechanisms behind the growth and metastasis of each cancer tumor type. ATCC offers a wide variety of cancer cell lines related to cancer genetics, early detection methods, and effective treatments of disease.
See our products for oncology drug development
Cancer research tools
Primary Immune Cells
ATCC has the primary immune cells, including peripheral blood mononuclear cells (PBMCs), you need to design and test cell-based assays and treatments as part of your research and development. A typical vial of PBMCs includes progenitor populations such as CD14+ monocytes and lymphocytes such as cluster of differentiation (CD) 19+ B cells, CD4+ helper T cells, CD8+ cytotoxic T cells, and CD56+ natural killer (NK) cells.
Learn More
Media and Reagents
ATCC high-performance media, sera, and reagents are uniquely formulated according to the cell growth conditions.
Get the Tools
